Vortioxetine (VOR) is a multimodal antidepressant drug. VOR is a 5-HT 3 -R, 5-HT 7 -R and 5-HT 1D -R antagonist, 5-HT 1B -R partial agonist, 5-HT 1A -R agonist, and serotonin transporter (SERT) inhibitor. VOR shows pro-cognitive activity in animal models and beneficial effects on cognitive dysfunction in major depressive patients. Here we compared the effects of 14-day treatments with VOR and escitalopram (ESC, selective serotonin reuptake inhibitor) on neuronal activity in the medial prefrontal cortex (mPFC). Ten groups of rats (5 standard, 5 depleted of 5-HT with p-chlorophenylalanine -pCPA-, used as model of cognitive impairment) were fed with control food or with two doses of VOR-containing food. Four groups were implanted with minipumps delivering vehicle or ESC 10 mg/kg$day s.c. The two VOR doses enable occupation by VOR of SERTþ5-HT 3 -R and all targets, respectively, and correspond to SERT occupancies in patients treated with 5 and 20 VOR mg/day, respectively. Putative pyramidal neurons (n ¼ 985) were recorded extracellularly in the mPFC of anesthetized rats.
Introduction
Vortioxetine (VOR) is a drug for the treatment of major depressive disorder (MDD) (Alvarez et al., 2012; Sanchez et al., 2015) that shows pro-cognitive efficacy in animal models Wallace et al., 2014; Westrich et al., 2015) and improves aspects of cognitive dysfunction in MDD patients (AlSukhn et al., 2015; Katona et al., 2012; McIntyre et al., 2014 McIntyre et al., , 2015 Mahableshwarkar et al., 2015a Mahableshwarkar et al., , 2015b Rosenblat et al., 2015) .
VOR is a 5-HT 3 , 5-HT 7 and 5-HT 1D receptor antagonist, 5-HT 1B receptor partial agonist, 5-HT 1A receptor agonist, and inhibitor of the serotonin (5-HT) transporter (SERT) (Mork et al., 2012; Sanchez et al., 2015) . Analyses of target occupancies in rodent brain and SERT occupancy data from human PET studies support a dosedependent occupancy of all these targets at clinical doses of vortioxetine .
VOR shows high affinity (3.7 nM) for 5-HT 3 -R (Mork et al., 2012) . 5-HT 3 -Rs are ion channels present in a subpopulation of cortical and hippocampal GABAergic interneurons located in the upper layers (Lee et al., 2010; Morales and Bloom, 1997; Puig et al., 2004) . 5-HT 3 -R physiological activation by endogenous 5-HT markedly excites a subpopulation of PFC GABA interneurons (Puig et al., 2004) .
VOR administration was shown to increase extracellular concentrations of monoamines in the forebrain to a greater extent than escitalopram (ESC, selective serotonin uptake inhibitor eSSRI-) Riga et al., 2016) , likely as a result of reducing the efficacy of local and distal negative feed-back mechanisms on monoamine systems. Furthermore, co-administration of an SSRI and a 5-HT 3 -R antagonist was shown to increase extracellular concentrations of 5-HT in mPFC and hippocampus to higher levels than the SSRI alone (Mork et al., 2012; Riga et al., 2016) . Moreover, acute VOR administration (but not ESC) dose-dependently was shown to enhance the discharge rate of midbrain-projecting pyramidal neurons in mPFC through a 5-HT 3 -R-dependent mechanism (Riga et al., 2016) . Given the control of midbrain serotonergic neurons by the mPFC (Celada et al., 2001) this effect may translate into a greater 5-HT neuronal activity, as observed after VOR administration (B etry et al., 2013) .
Given the action of VOR (but not ESC) on cognitive function in rodents, we examined the effect of subchronic VOR and ESC administration on neuronal discharge in the mPFC of rats in standard conditions (drug naive) and in rats depleted of 5-HT with the 5-HT synthesis inhibitor p-chlorophenylalanine (pCPA). This agent induces a cognitive deficit in rodents which is partially or totally reversed by VOR (du Jardin et al., 2014; Wallace et al., 2014) . Likewise, in order to relate the effects of the present study with those in treated patients, VOR was administered in the food, at two doses that result in occupation at SERT þ 5-HT 3 -R and all targets, respectively (Alan Pehrson, unpublished observations), and producing a SERT occupancy equivalent to that in patients treated with 5 mg/day and 20 mg/day VOR, respectively .
Material and methods

Animals
Male albino Wistar rats (175e200 g at the beginning of the treatment period) were used (Charles River, France). Animal care followed the European Union regulations (directive 2010/63 of 22 September 2010) and was approved by the Institutional Animal Care and Use Committee.
Drugs and treatments
Vortioxetine (VOR) hydrobromide and escitalopram oxalate (ESC) were provided by H. Lundbeck A/S. 4-chloro-DL-phenylalanine-methylester hydrochloride (pCPA) was from Sigma-Aldrich. VOR was administered p.o. in the food at doses of 0.26 g VOR/kg chow and 1.8 g VOR/kg chow. These doses evoke SERT occupancies in the rat (from 40-50% to 80e90%, respectively) similar to those achieved in patients treated with the clinical doses of 5 and 20 mg/ day VOR (Leiser et al., 2015; Wallace et al., 2014) . From 5 days before starting drug treatments, the regular rat chow was switched to Purina 5001 Rodent chow (control food), which had the same nutritional content as in the VOR-enriched chow (Leiser et al., 2015; Wallace et al., 2014) . Animals were fed ad libitum.
ESC was administered subcutaneously (s.c.) via osmotic minipump (Alzet, model M2L2) at the dose of 10 mg/kg$day (oxalate salt, corresponding to 7.5 mg/kg free base). Osmotic minipumps were implanted under anaesthesia (100 mg/kg Ketamine þ 10 mg/ kg Xylazine given i.p.). An analgesic (Buprenorfine: 0.5 mg/kg p.o every 12 h) and a prophylactic antibiotic (Enofloxacina 7.5 mg/kg s.c.) were given during 2e3 consecutive days after surgery.
At the beginning of treatments (day 1), animals were singlehoused and randomly assigned to one of the ten following experimental groups: 5 groups of standard rats treated with: 1) control food, 2) VOR-enriched food at low dose, 3) VOR-enriched food at high dose, 4) vehicle minipumps and 5) ESC minipumps, and 5 groups of pCPA-treated rats treated with the same treatments (groups 6e10). Treatments lasted two consecutive weeks (from day 1 to day 14). In the 5-HT depleted groups, the irreversible inhibitor of tryptophan hydroxylase pCPA (86 mg/kg free base, s.c.) was administrated daily during 4 consecutive days (from day 11 to day 14) in order to induce cognitive impairment through inhibition of 5-HT synthesis (du Jardin et al., 2014; Jensen et al., 2014; Wallace et al., 2014) . Neuronal recordings were performed in the mPFC 24 h after the last pCPA injection (day 15).
Electrophysiological recordings
Single unit extracellular recordings were performed with glass micropipettes at day 15 in chloral hydrate anesthetized rats (induction: 400 mg/kg i.p.; maintenance: 50e70 mg/kg/h i.p. using a perfusion pump), as previously described (Llad o-Pelfort et al., 2012; Riga et al., 2014 Riga et al., , 2016 . Putative pyramidal neurons in the mPFC were recorded during descending tracks performed at APþ3.2 to 3.4, L À0.7 from bregma; DV À1.5 to À4.8 mm from brain surface (Paxinos and Watson, 2005) . Once a spontaneously active neuron was detected at given AP and L coordinates, its discharge was recorded for at least 5 min. Then, the glass electrode was descended until a new spontaneously active neuron was detected and recorded. Individual firing rates were quantified by averaging the values of the last 2 min of each recording period. Typically, 1e4 tracks at different AP coordinates were performed during a 3e4 h recording period. Recordings were made between 10 a.m. and 4 p.m. DV coordinates of all recorded neurons were used to identify their location in prelimbic (PrL) and infralimbic (IL) subdivisions of the mPFC.
Single putative pyramidal neurons were selected on-line using standard criteria according with its long depolarization phase of the action potential and low symmetry (Llad o-Pelfort et al., 2012) . In order to avoid a potential contribution of fast spiking interneurons (FSI) to the data, we performed a second off-line analysis, using built-in and self-developed MATLAB routines. The identification of potential FSI was performed using the following characteristics of action potentials (average of spikes from 200 s in basal conditions): 1) duration of the depolarization phase (depolarization width, ms), 2) duration of the hyperpolarization phase (hyperpolarization width, ms) and 3) symmetry (ratio between depolarization (a) and hyperpolarization peaks (b); Fig. 1 ). Using these variables, neuronal clusters were made and compared with a cluster of FSI (n ¼ 17) previously recorded in the same setting (Llad o-Pelfort et al., 2012) . FSI showed the following characteristics: depolarization phase width: 0.30 ± 0.01 (SD ¼ 0.06) ms; hyperpolarization phase width: 0.77 ± 0.07 (SD ¼ 0.29) and symmetry 1.20 ± 0.14 (SD ¼ 0.56). Neurons meeting at least two of the following criteria: depolarization width >0.36 (mean þ SD of FSI; ms); hyperpolarization width > 1.08 (mean þ SD of FSI; ms); symmetry <0.64 or >1.76 (mean ± SD of FSI) were considered putative pyramidal neurons. A total of 985 neurons were included in statistical analyses. Table 1 shows the average number of neurons included from each experimental group.
Histology
At the end of the recording period, animals were euthanized by an anesthetic overdose. A piece of the mPFC (~30e100 mg) was dissected out, weighed and frozen at À80 C for subsequent analysis of the tissue 5-HT concentration, performed by high performance liquid chromatography (HPLC) of PFC homogenates, as described in Adell et al. (1989) .
Data and statistical analysis
Pyramidal discharge was quantified by averaging the values of the last 2 min periods of each neuronal recording (5 min). Firing rate data are given as spikes/s.
Tissue 5-HT concentrations in control and pCPA-depleted rats are given as fmol/mg tissue.
Data are expressed as mean ± SEM. Statistical analysis was performed using Student's t-test or two-way ANOVA (weight, pretreatment, treatment or mPFC area as main factors) followed by post-hoc analysis using Duncan's test, as appropriate. To examine drug effects on neuronal discharge, we carried out two different analyses, using all individual neurons recorded (n ¼ 985) and a single average value per rat (n ¼ 50), as stated in Results. The second statistical analysis was more stringent and was used to confirm the analysis using all recorded neurons. Statistical significance has been set at the 95% confidence level (two tailed).
Results
Effects of pharmacological treatments and implantation of subcutaneous minipumps on rat weight gain
To assess whether the pharmacological treatments used (pCPA, VOR, ESC) and/or the implantation of subcutaneous minipumps alter food intake in rats, we compared the weight gain (weight at day 15-wt at day 1, in g) considering all experimental groups (10 groups, 5 rats per group) ( Table 2) . Overall, pCPA pre-treatment altered rat weight gain, yet without significant differences between treatments. Hence, two-way ANOVA revealed a significant effect of pre-treatment (F(1,40) ¼ 11.64; p < 0.002), with no significant effect of the treatment (F(4,40) ¼ 1.66; p ¼ 0.1792) nor pretreatment x treatment interaction (F(4,40) ¼ 2.40; p ¼ 0.0658). The lower weight gain was seen in 5-HTedepleted rats bearing ESC minipumps (p < 0.05 vs control food in pCPA pre-treated rats and p < 0.002 vs ESC minipumps in standard rats; post-hoc test). No significant differences emerged between drug treatments and their respective controls (low and high VOR vs control food; ESC vs vehicle controls) for any of the pre-treatments (Table 2) .
Characterization of putative pyramidal neurons in mPFC
Putative pyramidal neurons were identified by comparing their action potential characteristics with those of a group of fast-spiking GABAergic interneurons (FSI) previously recorded in our laboratory (Llad o-Pelfort et al., 2012) . Putative pyramidal neurons showed higher depolarization and hyperpolarization widths than FSI (depolarization width: 0.56 ± 0.01 ms vs 0.30± 0.01 ms; hyperpolarization width: 1.21 ± 0.01 ms vs 0.77 ± 0.07 ms) and lower symmetry than FSI (2.32 ± 0.04 vs 1.20 ± 0.14, n ¼ 985 and n ¼ 17 for putative pyramidal neurons and FSI, respectively). Despite some overlap in one or other variable, both neuronal subsets were grouped into 2 clearly different clusters (blue and red points for putative pyramidal neurons and FSI, respectively; Fig. 1 ).
Effects of VOR and ESC on putative pyramidal neurons' activity in mPFC in standard and pCPA-treated rats
The magnitude of 5-HT depletion induced by pCPA in the PFC was 94% (804 ± 74 vs.48 ± 4 fmol/mg in control and pCPA-treated rats, respectively; n ¼ 25 each; p < 0.00001) similar to that found in recent studies (du Jardin et al., 2014; Jensen et al., 2014) .
Sub-chronic administration of low and high oral doses of VOR enhanced the discharge of the recorded neurons in standard and pCPA-treated rats (standard rats: 0.9 ± 0.1, 2.1 ± 0.2 and 1.3 ± 0.1 spikes/s in controls, low dose VOR and high dose VOR, respectively; pCPA-treated rats: 0.9 ± 0.1, 2.1 ± 0.2 and 1.8 ± 0.2 spikes/s, in controls, low dose VOR and high dose VOR, respectively; n ¼ 83e120 neurons/treatment). On the contrary, sub-chronic ESC treatment did not affect the firing rate of mPFC pyramidal neurons neither in standard nor in pCPA-treated rats (standard rats: from 0.8 ± 0.1 to 0.6 ± 0.1 spikes/s; pCPA-treated rats: from 0.8 ± 0.1 to 0.8 ± 0.1 spikes/s, for VEH and ESC minipumps, respectively; n ¼ 90e108 neurons/treatment). Fig. 2 shows representative examples of the recorded neurons in each experimental group. Two-way ANOVA revealed a significant effect of treatment on neuronal discharge (F(4,975) ¼ 39.99; p < 0.00001; n ¼ 985), and no significant effect of pre-treatment (F(1,975) ¼ 3.39; p ¼ 0.659) and pre-treatment x treatment interaction (F(4,975) ¼ 1.22; p ¼ 0.3011). Fig. 3A shows the results of post-hoc tests of VOR (all doses) vs. control food-treated rats (standard and pCPA pretreatment groups) and of high VOR in standard vs. pCPA-pretreated rats. A more stringent statistical analysis was performed, by calculating the mean discharge value per each rat, thus reducing dramatically degrees of freedom (from n ¼ 985 to n ¼ 50). Two-way ANOVA of this data set yielded essentially the same result, with a significant effect of treatment (F(4,40) ¼ 28.49; p < 0.00001; n ¼ 50), no significant effect of the pre-treatment (F(1,40) ¼ 2.99; p ¼ 0.0916) and pre-treatment x treatment interaction (F(4,40) ¼ 0.90; p ¼ 0.4727). Post-hoc analyses showed similar significant differences between groups as those found with all individual neuronal data (Fig. 3B) .
Individual neuronal data plotted in a linear Y-scale (Fig. 3C ) did not allow determination of whether the significant increase of discharge produced by VOR was a general effect or if it was due to a selective action on neurons with a very high discharge, which would then increase the mean value of the group. However, when the same data was plotted in a log scale (Fig. 3D) , the whole set of neuronal discharges was increased, allowing exclusion of the above possibility.
Differential effects of VOR on prelimbic (PrL) and infralimbic (IL) mPFC subdivisions
Given the increasing evidence that PrL and IL areas of the mPFC play a different role in the pathophysiology of major depression and possibly in its treatment (see Discussion), the data from all recorded neurons were split into two subpopulations according to their DV coordinate (PrL: À1.5 to À3.0; IL: À3.4 to À4.8; in mm from brain surface), excluding those in the border between both subdivisions (e.g., from À3.0 to À3.4 mm). In standard rats, two-way ANOVA revealed a significant effect of treatment (F(4,450) ¼ 23.84; p < 0.00001, n ¼ 460), no significant effect of area (F(1,450) ¼ 0.63; p ¼ 0.4289) and significant area Â treatment interaction (F(4,450) ¼ 2.42; p < 0.05). A significant post-hoc difference was observed between the effect of low-dose VOR in PrL and IL, with a higher increase of the discharge rate in IL in standard rats (IL: 0.7 ± 0.1 and 2.6 ± 0.4; PrL: 1.0 ± 0.1 and 1.9 ± 0.2 spikes/s, in control and low VOR dose rats, respectively) (Fig. 4B) . In pCPAtreated rats, two-way ANOVA revealed a significant effect of treatment (F(4,403) ¼ 13.25; p < 0.00001, n ¼ 413), area (F(1,403) ¼ 5.29; p < 0.03) but not of area Â treatment interaction (F(4,403) ¼ 1.53; p ¼ 0.1914). Post-hoc analysis revealed a significant increase in discharge in IL (from 1.2 ± 0.2 to 2.4 ± 0.5 spikes/s, for control and high VOR dose, respectively), but not in PrL, in rats treated with the high VOR dose (Fig. 4C) . Interestingly, the differences in neuronal discharge between doses observed in IL of standard rats disappeared in the IL of pCPA-treated rats.
Discussion
The present study shows that subchronic VOR treatment (but not ESC, given for the same time period at a dose that fully blocks SERT) increased the discharge of putative pyramidal neurons in rat mPFC. The oral VOR doses were chosen to mimic in the rat the levels of SERT occupancy achieved in depressed patients treated by a low and high clinical dose of VOR (5 and 20 mg/day, respectively). Previous studies have shown that the two oral doses result in a SERT occupancy in rat brain of approximately. 52.6 ± 2.2% and 98.2 ± 0.2% . According to the receptor occupancy data by vortioxetine (reviewed in Sanchez et al., 2015) , this corresponds to a full occupancy of 5-HT 3 -R at the lower dose plus a Data (g) are expressed as mean ± SEM. *p < 0.05 versus Control food in pCPA pre-treated rats; #p < 0.002 versus ESC minipumps in standard rats.
Fig. 2. Effect of sub-chronic vortioxetine (VOR) and escitalopram (ESC) treatments on
firing rate of putative mPFC pyramidal neurons. Representative histograms of recorded pyramidal neurons from standard and pCPA-treated rats administrated with control food, low and high VOR enriched food (0.26 and 1.8 g/kg of chow, respectively), vehicle (VEH) and ESC (10 mg/kg/day s.c.) filled osmotic minipumps. The firing rate (spikes/s) quantified by averaging the values of the last 2 min of each neuronal recording (5 min) is also shown.
partial occupancy of 5-HT 1B -R, 5-HT 1A -R and 5-HT 7 -R at the higher dose. The observed effects are, therefore, hypothesized to be representative of effects of clinical doses, with the obvious limitations of species differences. The increased discharge was observed in a large number of neurons per treatment group (from 85 to 120) and was very robust, since statistical analyses carried out with a single eaverage-value of neuronal discharge per rat (i.e., n ¼ 5 per group) revealed the same significant differences as analyses performed with the data from all recorded neurons. The large data deviation is unlikely to be caused by methodological reasons (chloral hydrate was continuously delivered by an infusion pump) and may reflect the diverse populations of pyramidal neurons recorded, in different cortical layers and with different inputs. The increase in pyramidal discharge was observed with low and high doses of VOR and in the two mPFC subdivisions, PrL and IL, although some differences between groups and treatments were noted. Likewise, VOR increased neuronal discharge in rats depleted of 5-HT with pCPA, which was used as a model of cognitive deficits (du Jardin et al., 2014; Wallace et al., 2014) .
The increased discharge of putative pyramidal neurons evoked by both VOR doses is in agreement with previous observations showing that cumulative i.v. doses of VOR dose-dependently increased the firing rate of midbrain-projecting pyramidal neurons in layer V of the mPFC (Riga et al., 2016) . This effect is mediated by 5-HT 3 -R blockade since it was prevented by the administration of the 5-HT 3 -R agonist SR57227A and was mimicked by the 5-HT 3 -R antagonist ondansetron and by ESC and ondansetron combinations (Riga et al., 2016) . Although we did not directly demonstrate the involvement of 5-HT 3 -R in the subchronic VOR effect, we assume it based on the acute experiments and on the receptor occupancy data produced by the low and high oral VOR doses. The cellular basis of this effect is the blockade of 5-HT 3 -R in a subpopulation of GABAergic interneurons located in upper cortical layers (Lee et al., 2010; Puig et al., 2004; Schweimer et al., 2016) an effect resulting in a reduction of GABA A -R-mediated inputs onto pyramidal neurons and their subsequent disinhibition. In our previous study (Riga et al., 2016) , we identified pyramidal neurons by antidromic stimulation from the midbrain, a technique that could not be applied here given the large number of neurons recorded. Therefore, we cannot exclude that the neuronal population included in the analyses contains a certain proportion of GABAergic interneurons, with discharge characteristics similar to that of pyramidal neurons. However, this proportion should be very low, in view of the following: 1) all GABAergic interneurons represent 15e20% of all cortical neurons, 2) putative FSI, which are mainly located in deep layers, were excluded from analyses, as described above, and 3) 5-HT 3 -R-expressing interneurons are located in layers IeIII, whereas tracks aimed at deep layers. Moreover, VOR reduces the discharge of the latter interneurons (Schweimer et al., 2016) , whereas a general enhancing effect of VOR was observed on neuronal discharge.
In agreement with these acute dosing experiments, subchronic VOR treatment increased neuronal discharge in standard rats. It also produced a similar enhancement in pCPA-treated rats, an observation difficult to reconcile with the antagonist character of VOR at 5-HT 3 -R (see below for extended discussion on this point). Interestingly, Wallace et al. (2014) reported that VOR improved the deficit in reversal learning induced by pCPA in rats. Although this effect was interpreted in terms of the partial agonist activity of VOR at 5-HT 1A -R and 5-HT 1B -R, the present results allow an alternative explanation, as follows. Primate studies have shown that the neurobiological substrate of short-term -or working-memory (an essential component of executive functions and a necessary step in long-term memory) is the emergence and maintenance of patterns of persistent neuronal activity in the dorsolateral PFC (equivalent to the PrL PFC in rodents). Hence, in primate experiments using visual working memory, the animals must remember the position of a visual stimulus on a screen during a delay period in the absence of the stimulus (Curtis and Esposito, 2003; Fuster and Alexander, 1971; Miller and Cohen, 2001; Wang et al., 2015) . The moderate increase of neuronal discharge induced by VOR in PrL PFC may facilitate the maintenance of these activity patterns associated to short-term memory and therefore contribute to its pro-cognitive effects. In support of this view, 5-HT 3 -R agonists impair shortterm and long-term memory in rats (Meneses, 2007) and the 5-HT 3 -R antagonists ondansetron and tropisetron improve memory consolidation (Meneses, 2003) . On the other hand, the effect of VOR on neuronal discharge may counteract the fall in working memory induced by psychological stress, associated with a reduced dorsolateral PFC activity, (Qin et al., 2009 ). However, alternative explanations may be equally valid, since psychotomimetic drugs produce a very large increase of pyramidal neurons discharge in mPFC (e.g., Kargieman et al., 2007) and cognitive enhancers may act via different neuronal mechanisms (Husain and Mehta, 2011) . In particular, the activation of 5-HT 1A -R by VOR may play an important role. 5-HT 1A -R agonists increase acetylcholine release (Izumi et al., 1994; Fujii et al., 1997; Koyama et al., 1999) , an effect that may explain the VOR-induced elevation of acetylcholine in acute microdialysis experiments (Mork et al., 2013) . However, using the subchronic oral dosing regimen of the present study VOR failed to produce a sustained extracellular elevation of acetylcholine (Pehrson et al., 2016) .
The similar effects of subchronic VOR treatment on neuronal discharge in standard and 5-HT-depleted rats suggest a similar antagonist action of VOR in both pre-treatment groups. However, an antagonist action is difficult to explain in rats with a very large degree (94%) of depletion of 5-HT stores, as produced by this treatment regime with pCPA. This raises the possibility that VOR interacts in a non-canonical way with 5-HT 3 -R. Interestingly, the 5-HT 3 -R antagonist ondansetron can antagonize peristaltic movements in reserpinized guinea pigs (Sia et al., 2013) . Although in different species and systems, both observations support the view that 5-HT 3 -R blockade may evoke cellular/molecular actions independent of the presence of 5-HT.
VOR was characterized in vitro as a high affinity antagonist at rat and human 5-HT 3A -R (Bang-Andersen et al., 2011; Sanchez et al., 2012) . However, 5-HT 3B -R subunits are largely co-expressed with 5-HT 3A -R in rodent brain (Doucet et al., 2007) and their association to 5-HT 3A -R subunits modifies channel properties, including the duration of the agonist response as well as agonist and antagonist affinities (Dubin et al., 1999) . More recently, it has been shown that the 5-HT 3B -R subunit confers spontaneous channel opening and alters ligand interaction with the receptor. Hence, the 5-HT analog 5-hydroxyindole acts as a partial agonist at 5-HT 3A -R and as an agonist or inverse agonist at 5-HT 3AB receptors (Hu, 2015; Hu and Peoples, 2008) . Likewise, the interaction of various 5-HT 3 -R ligands with palonosetron, a 5-HT 3 -R antagonist with slow dissociation kinetics, depends on the subunit composition (5-HT 3A or 5-HT 3AB ) (Lummis and Thompson, 2013) . Overall, these observations raise the possibility that VOR eand possibly other 5-HT 3 -R antagonists-interact with 5-HT 3 -R in a non-canonical form, e.g., stabilizing the inactive eclosed-form of the channel, even in the absence of 5-HT. This possibility is supported by the slow dissociation kinetics of VOR observed in in vitro electrophysiology studies in oocytes (Kristen Fredriksen, Lundbeck; personal communication) and would require appropriate experimental testing. Hence, it would be interesting to examine whether VOR and other 5-HT3-R antagonists (e.g., ondansetron, palonosetron) increase pyramidal neurons activity after acute treatment in rats depleted of 5-HT by various means (e.g., pCPA, 5,7-DHT, low tryptophan diet).
The IL and PrL subdivisions of the mPFC project to different subcortical areas (Vertes, 2004) and exert mutual inhibitory control. Hence, the optogenetic stimulation of pyramidal neurons in IL inhibited pyramidal neurons in PL (Ji and Neugebauer, 2012) . Despite this, VOR was able to increase the discharge of putative pyramidal neurons in both subdivisions. The increased discharge in PrL may be involved in the pro-cognitive actions of VOR, as discussed above. On the other hand, the IL subdivision is equivalent to the ventral anterior cingulate (vACC) in primate and human brain, which plays a key role in the pathophysiology and treatment of major depression. Hence, alterations of the energy metabolism have been reported in vACC (Drevets et al., 1997 (Drevets et al., , 2008 Seminowicz et al., 2004) and the deep brain stimulation of Broadman area 25, in the vACC, evokes a rapid improvement of major depressive patients refractory to antidepressant treatments (Mayberg et al., 2005; Puigdemont et al., 2011) . In rodents, this area also appears to play a major role in antidepressant-like treatments. Hence, local application of the non-competitive NMDA-R antagonist ketamine in IL evoked rapid and persistent antidepressant-like effects in rats, an action mimicked by the optogenetic stimulation of the same area (Fuchikami et al., 2015) . Likewise, the pharmacological blockade of the astroglial glutamate transporter GLT-1 in rat IL (but not in PrL) also evoked antidepressant like effects in the forced-swim and the novelty-suppressed feeding tests (Gasull-Camos et al., 2015) . Overall, these reports suggest that the increase of excitatory neurotransmission in the IL may contribute to the antidepressant effects of VOR but not ESC, in addition to the increase of forebrain monoaminergic neurotransmission (Mork et al., 2012; Riga et al., 2016) .
Interestingly, the differences in neuronal discharge between doses observed in IL of standard rats disappeared in the IL of pCPAtreated rats. Given the different target occupancies by low and high VOR doses (SERT þ 5-HT 3 -R and all targets, respectively), the different effect on IL discharge in standard rats, and the similar effect in pCPA-treated rats, the occupancy of non-5-HT 3 -R targets by endogenous 5-HT at high VOR doses may be responsible for the inverse relationship between VOR dose and neuronal discharge in IL.
Conclusions
In summary, the present study shows that subchronic treatment with VOR, but not ESC, increases neuronal activity in the two subdivisions of the mPFC, PrL and IL, in standard rats and in rats depleted of 5-HT with pCPA. The effect in PrL may account for the pro-cognitive activity of VOR in animal models whereas that in IL may contribute to the antidepressant effects of VOR, given recent observations indicating that the increased excitatory neurotransmission in this area evokes antidepressant-like effects in rodents. The use of VOR doses resulting in target occupancies similar to those observed in patients at clinical doses suggest that the increased neuronal discharge may also occur in human brain. The use of neuroimaging techniques (e.g., positron emission tomography scan, functional magnetic resonance imaging) for studies of these sub regions would allow the examination of vortioxetine effects on PFC activity in patients and whether they are associated to the improvement of cognitive deficits.
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